Scientists Uncover How Bacteria Build Better Cancer Drugs

Researchers have identified how bacterial enzymes use small “docking domains” as molecular connectors to naturally produce multiple versions of anti-cancer compounds — a finding that could help scientists engineer improved drugs, according to a study reported by ScienceDaily.

The work, led by Dr Munro Passmore at the University of Warwick’s Department of Chemistry, with Professor Greg Challis overseeing the project, was published in Nature Communications. It focuses on HDAC inhibitors, a family of cancer medicines that block enzymes involved in regulating gene expression. The FDA-approved blood-cancer treatment romidepsin belongs to this class.

Why the “connectors” matter

The team found that these docking domains allow different enzyme systems to communicate and cooperate, enabling bacteria to generate drug variants while preserving their effectiveness. Understanding that machinery, the researchers say, opens the door to designing synthetic pathways that could yield new candidates with better potency, improved selectivity and fewer side effects.

As Dr Passmore put it, the advance means scientists can begin to “engineer these drugs ourselves” — potentially accelerating development of treatments for cancers that are currently difficult to treat.

This report summarises a study published in Nature Communications, as covered by ScienceDaily. It is general science reporting and not medical advice.